Stopping DAPT After ACS
Research type
Research Study
Full title
Stopping dual anti-platelet treatment following acute coronary syndrome; a metabolic analysis.
IRAS ID
158423
Contact name
Jesse Dawson
Contact email
Research summary
Patients typically receive two anti-platelet drugs after a heart attack or bad angina episode. Platelets are small blood cell fragments that help blood to clot. We call this dual anti platelet therapy (or DAPT for short). After a period of time (between 1 and 12 months) patients will continue on only one anti-platelet drug (we call this monotherapy). We know that there is an increased risk of cardiovascular events when people stop DAPT and continue monotherapy. However, predicting the occurrence of this can be difficult and the mechanisms involved are not completely understood. This research aims to address these issues. We will recruit up to 200 patients who will have blood and urine sampled before and after cessation of DAPT. We will perform a detailed analysis of patients blood samples to see if we can identify differences in levels of molecules related to platelets after DAPT is stopped. This may allow us to identify those at risk of problems after DAPT stops.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
14/NW/1163
Date of REC Opinion
28 Jul 2014
REC opinion
Favourable Opinion